Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/ddr.21676 http://scihub22266oqcxt.onion/10.1002/ddr.21676 32337769!7267448!32337769     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Drug+Dev+Res 2020 ; 81 (7): 765-767 Nephropedia Template TP {{tp|p=32337769|t=2020. Noscapine, a possible drug candidate for attenuation of cytokine release associated with SARS-CoV-2 |pdf=|usr=}}{{32337769}} gab.com Text Noscapine, a possible drug candidate for attenuation of cytokine release associated with SARS-CoV-2 JO: Drug Dev Res http://www.kidney.de/pget.php?&tw=1&pmid=32337769 #FOAvip Successful treatment of viral infections has proven to be huge challenge for modern medicine with the most effective approach being prior vaccination. The problem with vaccination is the time it takes to develop an effective vaccine, validate its safety and manufacture it in large quantities. Facing Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), we simply do not have the time to develop the vaccine before thousands of people die. Therefore, any treatment which can decrease the severe symptoms due to lung damage may help attenuate mortality rates. Inactivation of ACE2 during virus fusion into the host cell may be one of the underlying reasons for intense immunological reaction seen in the lung tissue. This overreaction is probably mediated through the bradykinin receptor activation. Noscapine, a medication used for the treatment of cough, has been shown to inhibit bradykinin enhanced cough response in man. As it is already marketed in a number of countries as a cough medicine, even for children, a suitable formulation with all the required licenses is available that can be rapidly utilized in preliminary trials. Twit Text FOAVip Noscapine, a possible drug candidate for attenuation of cytokine release associated with SARS-CoV-2 ????Drug Dev Res http://www.kidney.de/pget.php?&tw=1&pmid=32337769 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32337769 #FOAvip English Wikipedia <ref>{{Cite pmid|32337769}}</ref> Noscapine, a possible drug candidate for attenuation of cytokine release associated with SARS-CoV-2 #MMPMID32337769 Ebrahimi SA Drug Dev Res 2020[Nov]; 81 (7): 765-767 PMID32337769show ga Successful treatment of viral infections has proven to be huge challenge for modern medicine with the most effective approach being prior vaccination. The problem with vaccination is the time it takes to develop an effective vaccine, validate its safety and manufacture it in large quantities. Facing Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), we simply do not have the time to develop the vaccine before thousands of people die. Therefore, any treatment which can decrease the severe symptoms due to lung damage may help attenuate mortality rates. Inactivation of ACE2 during virus fusion into the host cell may be one of the underlying reasons for intense immunological reaction seen in the lung tissue. This overreaction is probably mediated through the bradykinin receptor activation. Noscapine, a medication used for the treatment of cough, has been shown to inhibit bradykinin enhanced cough response in man. As it is already marketed in a number of countries as a cough medicine, even for children, a suitable formulation with all the required licenses is available that can be rapidly utilized in preliminary trials. |Angiotensin-Converting Enzyme 2/metabolism[MESH] |Bradykinin/*antagonists & inhibitors/metabolism[MESH] |COVID-19 Drug Treatment[MESH] |COVID-19/*immunology[MESH] |Cytokines/metabolism[MESH] |Down-Regulation[MESH] |Humans[MESH] |Noscapine/*pharmacology/therapeutic use[MESH] |Receptors, Bradykinin/metabolism[MESH] |SARS-CoV-2/*immunology[MESH]Noscapine, a possible drug candidate for attenuation of cytokine relea(epmc).pdf DeepDyve Pubget Overpricing